Introduction {#Sec1}
============

Common variable immunodeficiency (CVID) is one of the most frequently diagnosed primary immunodeficiencies (PIDs), and is defined as decreased serum immunoglobulin (Ig) G, decreased IgA and/or IgM, poor antibody responses to vaccines, and exclusion of other causes of hypogammaglobulinemia^[@CR1]^. Patients commonly experience recurrent (sinopulmonary) infections and features of immune dysregulation such as autoimmunity^[@CR1],\ [@CR2]^. About 25% of CVID patients are diagnosed in childhood^[@CR3]^. To rule out transient hypogammaglobulinemia of infancy, in which Ig levels spontaneously resolve mostly by the age of two to four years, a definite diagnosis of CVID should not be given before the age of four years^[@CR1]^.

Here, we report novel familial cases of Wiedemann-Steiner syndrome (WSS) and Roifman syndrome (RS) that were initially categorized as early-onset CVID. WSS and RS are rare syndromic PIDs, affecting the immune system as well as other organ systems^[@CR4]--[@CR6]^. Although there is considerable phenotypic heterogeneity in both syndromes, hallmark extra-immunological features are generally evident very early in life^[@CR7],\ [@CR8]^. WSS is typically characterized by *hypertrichosis cubiti*, growth retardation, developmental delay and facial dysmorphism, and is caused by heterozygous mutations in *lysine methyltransferase 2*  *A* (*KMT2A*)^[@CR7],\ [@CR9]--[@CR14]^. *KMT2A* (also called *mixed-lineage leukemia*, *MLL*) encodes a histone methyltransferase involved in regulating chromatin-mediated transcription and is a frequent target of chromosomal rearrangements in childhood leukemia^[@CR9],\ [@CR15]^. WSS has only been recently associated with primary antibody deficiency^[@CR7]^. RS, on the other hand, is commonly featured by antibody deficiency as well as growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy^[@CR8],\ [@CR16]^. Biallelic mutations in *RNU4ATAC*, a noncoding small nuclear RNA (snRNA) gene, were recently identified as a cause of RS^[@CR8]^. U4atac snRNA is an important component of the minor spliceosome required for minor intron splicing^[@CR8]^.

This report aspires to increase awareness among immunologists and geneticists that a CVID phenotype can be the principal presentation of WSS and RS in early childhood, which is exceptional and has not been previously reported. The prior diagnosis of early-onset CVID diverted attention away from the initially less evident extra-immunological features, which significantly delayed identification of the underlying syndromic disorders. Additionally, in both families we identified mutations that have not been previously associated with disease. We aimed to provide insight as to how these mutations are disease-causing. Finally, we expand the immunophenotypical spectrum of WSS and RS, which could support future mechanistic research.

Results {#Sec2}
=======

An early-onset CVID phenotype in two unrelated sibling pairs {#Sec3}
------------------------------------------------------------

This study reports on two unrelated sibling pairs with recurrent respiratory tract infections and antibody deficiency categorized as CVID in early childhood. The family A monozygotic twin boys (Fig. [1a](#Fig1){ref-type="fig"}, II:2 and II:3) were born prematurely at 34 weeks gestational age to non-consanguineous, Belgian parents and are currently 11 years old. One of them (II:3) was born with bilateral inguinal hernia and hypospadias, which were attributed to his premature birth. From the first year of life, the twin boys suffered from recurrent upper and lower respiratory tract infections, often requiring antibiotics. At 2 months of age, patient II:3 developed severe pneumonia with respiratory arrest and heart failure. The latter led to the recognition of a patent *ductus arteriosus*, which was surgically ligated shortly thereafter. The postoperative course was complicated by severe respiratory distress requiring ventilation and systemic corticosteroids. Upon immunological evaluation, both patients II:2 and II:3 demonstrated panhypogammaglobulinemia, poor antibody responses to Pneumococcal polysaccharide vaccine, increased naive B cells, and very low memory B cells (Table [1](#Tab1){ref-type="table"}). Additionally, both patients showed evidence of mild bronchiectasis on high-resolution computed tomography (HRCT) scan at 3.5 years of age.Figure 1Family A with *KMT2A*-associated Wiedemann-Steiner syndrome (WSS). (**a**) Pedigree of family A. (**b**) Skipping of *KMT2A* exon 28. Gel electrophoresis of the *KMT2A* cDNA region containing exon 28 revealed a second shorter transcript in the three affected individuals. HC1 and HC2 represent two healthy controls; *GAPDH* was used as reference target. In-frame deletion of exon 28 was confirmed by cDNA sequencing; c.10755 and c.10835 indicate the start respectively stop position of exon 28. (**c**) KMT2A protein domains (adapted from ref. [@CR9]). KMT2A is cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which form a non-covalently associated complex. Deletion of the amino acids encoded by exon 28 may disrupt the interaction site between the two fragments. Table 1Routine immunological laboratory results of the family A patients with Wiedemann-Steiner syndrome.Patient II:2Patient II:3Patient I:2ValueReference rangeValueReference rangeValueReference range**White blood cells***Age: 8 yearsAge: 8 yearsAge: 45 years*  Total leukocytes (no./µL)119306000--1400073406000--1400072103650--9300  Neutrophils (no./µL)69802000--800031502000--800034501573--6100  Lymphocytes (no./µL)39901500--750034801500--750028701133--3105    CD3+ T cells (no./µL)2630700--42002580700--42002240700--2100      CD3+ CD4+ T helper cells (no./µL)1600300--20001640300--20001120300--1400        CD45RA + naive CD4 + T cells (%)8246--77^†^8246--77^†^44NA        CD45RO+ memory CD4+ T cells (%)1213--30^†^1013--30^†^50NA      CD3+ CD8+ T cytotoxic cells (no./µL)838300--1800800300--18001060200--1200        CD45RA+ naive CD8+ T cells (%)8063--92^†^6963--92^†^26NA        CD45RO+ memory CD8+ T cells (%)124--21^†^104--21^†^73NA    CD19+ B cells (no./µL)798200--1600592200--1600287100--500      IgD + CD27- naive B cells (%)9647.3--77.0^‡^9447.3--77.0^‡^8848.4--79.7^‡^      CD24 + + CD38++ transitional B cells (%)194.6--8.3^‡^104.6--8.3^‡^140.9--5.7^‡^      IgD − CD27+ switched memory B cells (%)110.9--30.4^‡^110.9--30.4^‡^68.3--27.8^‡^      IgD + CD27+ marginal zone B cells (%)25.2--20.4^‡^25.2--20.4^‡^37.0--23.8^‡^      CD21^low^ CD38^low^ B cells (%)22.3--10.0^‡^32.3--10.0^‡^21.6--10.0^‡^    CD3 − CD56 + CD16+ NK cells (no./µL)47990--90024490--90034490--600  Monocytes (no./µL)690700--1500570700--1500780247--757  Eosinophils (no./µL)220200--500100200--5008028--273  Basophils (no./µL)3010--1002010--100106--50**Immunoglobulins**\**Age: 7 yearsAge: 3 yearsAge: 45 years*    IgG (g/L)3.64.70--10.52.84.70--9.307.67.0--16.0    IgG2 (g/L)1.130.85--4.100.540.63--3.03.031.50--6.40    IgG3 (g/L)0.2650.13--1.420.1760.13--1.260.3070.20--1.10    IgM (g/L)\<0.20.27--0.63\<0.20.27--0.57\<0.180.40--2.48    IgA (g/L)0.30.50--1.410.30.41--0.912.350.71--3.65    IgE (kU/L)\<4.40--90\<4.40--60NA**Specific antibody responses**\**Age: 7 yearsAge: 3 yearsAge: 45 years*    *S*. *pneumoniae* polysaccharide IgG (Lab U)NA9≥11: immuneNA    *S*. *pneumoniae* polysaccharide IgG: specific IgG response to 3 serotypes (8, 9 N, 15B)Insufficient antibody response2x titer increase for at least 2 out of 3 serotypesNAGood antibody response2x titer increase for at least 2 out of 3 serotypes   Tetanus IgG (IU/mL)0.01 ≥ 0.01: immune0.03 ≥ 0.01: immune0.50 ≥ 0.01: immune   Rubella IgG (IU/mL)12\>10: immune44\>10: immuneNA   Measles IgG (mIU/mL)350\>300: immune1200\>300: immuneNA   Mumps IgG (Lab U/mL)270\>500: immune540\>500: immuneNA   Varicella Zoster IgG (mIU/mL)620\>100: immune1400\>100: immuneNA**Lymphocyte proliferation assay***Age: 3 yearsAge: 3 years*   Response to Concanavalin ANormalCompared to controlNormalCompared to controlNA   Response to PhytohemagglutininNormalCompared to controlNormalCompared to controlNA   Response to Tetanus toxoidNormalCompared to controlModerately reducedCompared to controlNAThe most recent, comprehensive and representative laboratory results are shown for each patient. Patients II:2 and II:3 were immunized according to the recommended Belgian childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. Patient I:2 had received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal vaccine was given to patients II:2 and I:2 at time of immunological evaluation; patient I:2 had never received a pneumococcal vaccine before then. Patients II:2 and II:3 were not vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. \*Measured when not receiving immunoglobulin replacement therapy. ^†^Reference values from Shearer *et al*.^[@CR27]^. ^‡^Reference values from Piatosa *et al*.^[@CR28]^.

The family B brother and sister pair (Fig. [2a](#Fig2){ref-type="fig"}, II:1 and II:2) were born to healthy, non-consanguineous, Belgian parents and are currently 17 and 14 years of age respectively. They had recurrent upper and lower respiratory tract infections since the age of 18 months (II:1) and 3 years (II:2). The girl (II:2) also had recurrent gastroenteritis in early childhood and diffuse atopic eczema since infancy. Similar to the family A sibling pair, they had panhypogammaglobulinemia and poor global antibody responses to Pneumococcal polysaccharide vaccine (Table [2](#Tab2){ref-type="table"}). Serotype-specific Pneumococcal antibody responses were not evaluated. In contrast to the family A twins, the family B siblings demonstrated severe B cell lymphopenia with normal switched memory B cell percentages and increased CD21^low^ B cell levels (Table [2](#Tab2){ref-type="table"}). HRCT scan in patient II:1 at the age of 7.5 years displayed marked bronchiectasis, whereas his sister (II:2) only showed discrete bronchiectasis at a similar age.Figure 2Family B with *RNU4ATAC*-associated Roifman syndrome (RS). (**a**) Pedigree of family B. (**b**) Representative retinal images of the RS patients. Panel I, composite retinal image of fundus of left eye (LE) of patient II:1: note inferior outer retinal atrophy with greyish hue and intraretinal pigment migration of the spicular type in inferior retina; mottled aspect of retinal pigment epithelium, more pronounced in inferotemporal area. Panel II, blue light autofluorescence image of LE of patient II:1 showing hyperautofluorescent delineation of inferior atrophic zone, as well as superior to optic disc, illustrating more widespread disease than can be seen on white light fundoscopic image only. Panel III, similar image of right eye (RE) of patient II:1 as in Panel II. Panel IV, fundus picture of detail of superonasal midperiphery of RE of patient II:2. Despite a normal full-field flash electroretinography, recent fundus examination at 14 years of age showed a mild mottling of pigment epithelium suggestive of early stage retinal dystrophy. (**c**) U4atac snRNA showing structural elements, conserved positions and location of variants associated with RS (adapted from ref. [@CR8]). The here-reported variant that has not been previously associated with RS is shown in red. Table 2Routine immunological laboratory results of the family B patients with Roifman syndrome.Patient II:1Patient II:2ValueReference rangeValueReference range**White blood cells***Age: 14 yearsAge: 11 years*  Total leukocyte count (no./µL)77204500--1200098004500--12000  Neutrophils (no./µL)52902500--800060802500--8000  Lymphocytes (no./µL)11901500--650024101500--6500    CD3+ T cells (no./µL)940800--35001740800--3500      CD3 + CD4+ T helper cells (no./µL)643400--21001080400--2100        CD45RA+ naive CD4+ T cells (%)5533--66^†^6833--66^†^        CD45RO+ memory CD4+ T cells (%)3818--38^†^2718--38^†^      CD3 + CD8+ T cytotoxic cells (no./µL)274200--1200603200--1200        CD45RA+ naive CD8+ T cells (%)6061--91^†^6761--91^†^        CD45RO+ memory CD8+ T cells (%)334--23^†^224--23^†^    CD19+ B cells (no./µL)36200--60048200--600      IgD + CD27- naive B cells (%)7751.3--82.5^‡^7051.3--82.5^‡^      CD24 + + CD38++ transitional B cells (%)151.4--13.0^‡^51.4--13.0^‡^      IgD-CD27+ switched memory B cells (%)98.7--25.6^‡^108.7--25.6^‡^      IgD + CD27+ marginal zone B cells (%)44.6--18.2^‡^14.6--18.2^‡^      CD21^low^ CD38^low^ B cells (%)222.7--8.7^‡^212.7--8.7^‡^    CD3-CD56 + CD16+ NK cells (no./µL)17970--120055470--1200  Monocytes (no./µL)910500--1000960500--1000  Eosinophils (no./µL)290100--500230100--500  Basophils (no./µL)2010--1009010--100**Immunoglobulins**\**Age: 3 yearsAge: 6 years*   IgG (g/L)3.84.7--9.34.44.7--10.5   IgG2 (g/L)0.530.63--3.00.490.85--4.1   IgG3 (g/L)0.0210.13--1.260.2420.13--1.42   IgM (g/L)\<0.20.27--0.570.30.27--0.63   IgA (g/L)0.30.41--0.91\<0.30.5--1.41  IgE (kU/L)\<4.40--60\<4.40--90**Isohemagglutinins**\**Age: 3 years*  ABO blood typeONA  Anti-A IgMNegativePositiveNA  Anti-B IgMNegativePositiveNA**Specific antibody responses**\**Age: 3 yearsAge: 6 years*  *S*. *pneumoniae* polysaccharide IgG (Lab U)\<3 ≥ 11: immune7 ≥ 11: immune  Tetanus IgG (IU/mL)0.03 ≥ 0.01: immune1 ≥ 0.01: immune  Rubella IgG (IU/mL)\<8\>10: immuneNA  Measles IgG (mIU/mL)\<150\>300: immuneNA  Mumps IgG (Lab U/mL)\<230\>500: immuneNA  Varicella zoster IgG (mIU/mL)360\>100: immune1400\>100: immune**Lymphocyte proliferation assay***Age: 9 yearsAge: 6 years*  Response to Concanavalin ANormalCompared to controlNormalCompared to control  Response to PhytohemagglutininNormalCompared to controlNormalCompared to control  Response to Tetanus toxoidNormalCompared to controlNormalCompared to controlThe most recent, comprehensive and representative laboratory results are shown for each patient. Both patients were immunized according to the recommended Belgian childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. A polysaccharide (unconjugated) pneumococcal vaccine was given at time of immunological evaluation. The patients were not vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. \*Measured when not receiving immunoglobulin replacement therapy. ^†^Reference values from Shearer *et al*.^[@CR27]^. ^‡^Reference values from Piatosa *et al*.^[@CR28]^.

In both the family A and B sibling pairs, the clinical presentation and laboratory findings in the first years of life were reminiscent of a CVID phenotype. All patients are currently doing well under regular Ig replacement therapy, antiflogistic maintenance treatment with azithromycin and intermittent inhaled corticosteroids and/or short-acting beta-agonists therapy.

Extra-immunological features raised suspicion of syndromic PID {#Sec4}
--------------------------------------------------------------

Although both sibling pairs first presented with a phenotype resembling CVID, with time they gradually demonstrated additional clinical features not typically associated with CVID (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). The family A twin boys developed a third degree atrioventricular block for which a pacemaker was implanted at 5 (II:3) and 6.5 (II:2) years of age respectively. In the following years, the boys showed increasing evidence of mild intellectual disability. In retrospect, patient II:3 had signs of mild developmental delay during the first years of life. Both twins also demonstrated poor weight gain and growth retardation, albeit to a limited extent. Around the age of 9 years, dysmorphic facial features became more conspicuous (Table [3](#Tab3){ref-type="table"}). Interestingly, the twins' mother (I:2) had congenital urogenital tract anomalies consisting of a unicornuate uterus and a unique left ovary, fallopian tube and kidney. Moreover, since childhood, she had suffered from right unilateral sensorineural hearing loss as well as recurrent sinusitis and bronchitis frequently requiring antibiotics. At that time, genetic or immunological testing had never been performed in the mother as she deemed herself to be in good general health. The twins' older brother (II:1) and father (I:1) had an uneventful medical history.Table 3Comparison of the family A patients with published cases of *KMT2A*-associated Wiedemann-Steiner syndrome.Clinical features^†^18 published patients^[@CR7],\ [@CR9]--[@CR14]^Present studyPatient II:2Patient II:3Patient I:2Gender8 M, 10 FMMFAge at last examination (years)1--24111146Short stature18/18+++*Craniofacial features*   Microcephaly2/7−−−   Mild macrocephalyNA++− Hypertelorism, telecantus9/17+++   Down-slanted palpebral fissures14/16+++   Vertically narrow palpebral fissures13/17+++   Strabismus4/17−−−   Thick eyebrows14/17+++   Wide nasal bridge16/18+++   Broad nasal tip11/17+++   Long philtrum2/12−−−   Thin upper lip6/12+++   Low-set ears2/12+++   Abnormal dentition, hypodontia5/9−−−   High palate4/8+++   Micrognathia7/11+++*Musculoskeletal features*   Advanced bone age1/16NANANA   Small hands and feet5/17+++   Fleshy hands and feet3/7+++   Clinodactyly8/18−++   Congenital hip dysplasia2/17−−−   Muscular hypotonia9/18−−−*Dermatological features*   Thick hair14/17+++   *Hypertrichosis cubiti*13/18−−−   Hypertrichosis back and/or lower limbs16/18−−−*Neurological features*   Developmental or psychomotor delay18/18−+NA   Intellectual disability16/17+++   Autism2/12−−−   Aggressive behavior4/13−−−   Hyperactivity2/12−−−   Seizures1/7−−−*Internal organ anomalies*   Cardiovascular anomalies3/17++−   Urogenital anomalies4/17−++   Intestinal anomalies4/11−−−   Feeding difficulties10/18++−*Immunodeficiency features*   Antibody deficiency1/1+++   Respiratory tract infections2/17+++   Urinary tract infections4/18−−−   BronchiectasisNA++NANA: not available. ^†^Not all clinical features have been ascertained in all previously published patients. Adapted from Stellacci *et al*.^[@CR7]^. Table 4Comparison of the family B patients with published cases of *RNU4ATAC*-associated Roifman syndrome.Clinical features6 published patients^[@CR8]^Present studyPatient II:1Patient II:2Gender5 M, 1 FMFAge at last examination (years)NA1714*Growth retardation*   Prenatal, intra-uterine growth retardation6/6NANA   Postnatal growth retardation6/6++*Craniofacial features*   Mild microcephaly5/6++   Long philtrum6/6++   Thin upper lips6/6++   Narrow, tubular and upturned nose6/6++*Ophthalmological features*   Retinal dystrophy3/6++*Musculoskeletal features*   Epiphyseal dysplasia6/6+−   Vertebral changes3/6+−   Coxa varaNA+−   Agenesis of anterior cruciate ligamentsNA+−   Agenesis of 12^th^ ribsNA+−   Short metacarpals6/6+−   5^th^ digit clinodactyly4/6−−   Brachydactyly6/6+−   Transverse palmar crease5/6−−   Muscular hypotonia5/6−−*Neurological features*   Intellectual disability, cognitive delay5/6−−   Sensorineural hearing loss1/6−−*Internal organ anomalies*   Noncompaction of the myocardium1/6−−   Ventricular septum defect (VSD)1/6−−   Lung hypoplasiaNA−+*Immunodeficiency and atopic features*   Antibody deficiency6/6++   Hepatosplenomegaly5/6−−   BronchiectasisNA++   Eczema3/6−+NA: not available.

Analogously, the boy in family B (II:1) initially displayed subtle syndromic features, such as mild growth retardation, that appeared more pronounced over time. At the age of seven years, diverse skeletal abnormalities including spondyloepiphyseal dysplasia were detected (Table [4](#Tab4){ref-type="table"}). At the same age, he was also found to have slowly progressive retinal dystrophy (Fig. [2b](#Fig2){ref-type="fig"}, Panels I-III) with decreased rod function but near-normal cone function on full-field flash electroretinography. Antibody deficiency in combination with skeletal and ophthalmological features led to the clinical suspicion of RS in the boy. However, his sister (II:2) had no radiographic sings of spondyloepiphyseal or hip dysplasia nor retinal dystrophy. Moreover, RS was originally presumed to be an X-linked recessive condition, although no causal gene had been identified^[@CR16]^. When the family B girl (II:2) was about 9 years old, Gray *et al*. reported the first female patient with RS, having a skewed X-inactivation and a milder phenotype than her affected brother^[@CR17]^. Subsequently, we hypothesized that patient II:2 might be a manifesting heterozygote of RS, which could be compatible with her milder extra-immunological phenotype at that time.

Cytogenetic and cytogenomic analyses were negative in both sibling pairs {#Sec5}
------------------------------------------------------------------------

In the family A twins, conventional G-banding karyotype, fluorescent *in situ* hybridization for region 22q11.2 and subtelomeric screening were normal. Furthermore, microarray-based comparative genomic hybridisation analysis in both sibling pairs did not demonstrate copy number variations.

Whole exome sequencing (WES) uncovers WSS in family A {#Sec6}
-----------------------------------------------------

Since no specific genetic syndrome was suspected in family A, WES was performed in patient II:2 and both parents. This revealed a heterozygous splice site variant in *KMT2A* (NM_001197104:c.10835 + 1 G \> A), present in the twins (II:2, II:3) as well as in the mother (I:2) (Fig. [1a](#Fig1){ref-type="fig"}). The variant is not reported in public or in-house databases. The *KMT2A* nucleotide substitution is situated in the splice donor site of intron 28. *In silico* splicing prediction tools suggested complete loss of the splice donor site resulting in exon 28 skipping and an in-frame deletion of 81 bp, which was confirmed by analyses on cDNA derived from patients' PBMCs (Fig. [1b](#Fig1){ref-type="fig"}). Mature KMT2A protein is physiologically cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which together form a non-covalently associated complex (Fig. [1c](#Fig1){ref-type="fig"})^[@CR15],\ [@CR18]^. Complex formation is necessary for stability and subnuclear localization of the protein^[@CR18]^. The amino acids encoded by exon 28 are part of the interaction site between KMT2A-N and KMT2A-C (Fig. [1c](#Fig1){ref-type="fig"})^[@CR15]^. It has been shown that disrupting the interaction between the two fragments causes degradation of the KMT2A-N fragment and loss of protein function^[@CR18]^. The KMT2A-N fragment was only very weakly detectable by western blot on PBMC lysates, however, and could therefore not be reliably interpreted (data not shown). Subsequent investigations in the mother demonstrated mild intellectual disability, undetectable serum IgM, and reduced switched memory B cells (Table [1](#Tab1){ref-type="table"}). Taken together, the c.10835 + 1 G \> A variant in *KMT2A* indicates a molecular diagnosis of WSS in the twin brothers and their mother.

Targeted sequencing confirms the diagnosis of RS in family B {#Sec7}
------------------------------------------------------------

In family B, WES was unable to identify a potentially disease-causing variant. In 2015, biallelic mutations in *RNU4ATAC* were identified in patients with RS^[@CR8]^. Since *RNU4ATAC* is a noncoding snRNA gene, possible variants would have been missed with WES. Indeed, subsequent Sanger sequencing of *RNU4ATAC* revealed compound heterozygous variants in both siblings (c.13 C \> T and c.116 A \> T) that segregated in the parents (Fig. [2a](#Fig2){ref-type="fig"}). The c.13 C \> T variant (rs559979281) had been previously reported in RS (Fig. [2c](#Fig2){ref-type="fig"})^[@CR8]^. The c.116 A \> T variant has, to our knowledge, not yet been associated with human disease. The public database gnomAD (Genome Aggregation Database) contains two heterozygotes for the c.116 A \> T variant (allele frequency of 0.00001531) but no homozygotes. Importantly, the c.116 A \> T variant is located in a highly conserved position involved in splicing activity (Fig. [2c](#Fig2){ref-type="fig"})^[@CR8]^. Furthermore, position 116 is immediately adjacent to the Sm protein-binding site, which is a highly conserved structural element essential in splicing activity and previously implicated in RS (Fig. [2c](#Fig2){ref-type="fig"})^[@CR8]^. Together, the *RNU4ATAC* genotype confirms the diagnosis of RS in the family B siblings.

Immunological abnormalities in the WSS and RS patients {#Sec8}
------------------------------------------------------

Because of the prominent immunodeficiency in both sibling pairs, we performed flow cytometric analysis of B and T lymphocyte subsets as previously described^[@CR19]^. Interestingly, all patients from families A and B had decreased circulating follicular helper T (cTfh) cells (Fig. [3a,b](#Fig3){ref-type="fig"}). Tfh cells play an essential role in the formation of antibody-producing plasma cells and memory B cells^[@CR20]^. Furthermore, the two RS patients showed markedly reduced expression levels of B cell activating factor-receptor (BAFF-R), a receptor important in peripheral B cell survival (Fig. [3b](#Fig3){ref-type="fig"})^[@CR21]^. The WSS patients had normal BAFF-R levels (Fig. [3a](#Fig3){ref-type="fig"}). Expression of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), a receptor related to BAFF-R, was normal in both the WSS and RS patients (Fig. [3a,b](#Fig3){ref-type="fig"})^[@CR21]^. For all patients, the alterations in naive and memory lymphocyte subsets (Supplementary Figs [1](#MOESM1){ref-type="media"}--[4](#MOESM1){ref-type="media"}) corresponded with those seen in the routine laboratory assessment (Table [1](#Tab1){ref-type="table"}). Other examined B and T cell populations fell within the range of the age-matched healthy controls (Supplementary Figs [1](#MOESM1){ref-type="media"}--[4](#MOESM1){ref-type="media"}).Figure 3cTfh cells, BAFF-R expression and TACI expression in WSS and RS patients. (**a**) Family A patients with *KMT2A*-associated Wiedemann-Steiner syndrome (WSS). The twins (II:2, II:3) were 8 years old and the mother (I:2) was 43 years old at time of analysis. (**b**) Family B patients with *RNU4ATAC*-associated Roifman syndrome (RS). At time of analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. Flow cytometric immunophenotyping was performed on patients' PBMCs in comparison with age-matched healthy controls (HC). T cells were gated as CD3^+^ and B cells as CD19^+^CD20^+^ in total PBMCs. Circulating follicular helper T (cTfh) cells were gated as CXCR5^+^CD45RO^+^ in CD4^+^ T cells. BAFF-R and TACI expression were measured on B cells. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of the HC groups represent mean ± standard deviation. BAFF-R: B cell activating factor-receptor, cTfh: circulating follicular helper T, expr: expression, TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor.

Discussion {#Sec9}
==========

We report two sibling pairs with an early-onset CVID phenotype as primary and cardinal presentation of WSS and RS: recurrent sinopulmonary infections, panhypogammaglobulinemia, reduced polysaccharide vaccine responses, and aberrant peripheral B cell subsets^[@CR1]^. Because extra-immunological features were initially subtle and only became conspicuous with age, the establishment of an accurate diagnosis was significantly delayed. Therefore, we recommend to proactively evaluate all paediatric patients with a CVID phenotype for extra-immunological syndromic features, especially when presenting at an early age. In particular, diagnostic workup should include evaluation by a clinical geneticist, in addition to orthopedic, cardiologic, neurologic, urogenital and ophthalmologic assessment. To reach a conclusive diagnosis, genetic testing should be performed, varying from targeted testing of a specific disease gene to WES. Here, the diagnosis of WSS in family A was only confirmed upon WES in affected family members^[@CR7],\ [@CR9]^. In family B on the other hand, WES failed to reveal the causal genetic defect because this was located in a noncoding gene^[@CR8]^. Targeted testing of the known disease gene for RS allowed to identify the underlying mutations and to provide a definite diagnosis^[@CR8]^. Of note, if WES does not identify a genetic defect and there is no known disease gene, whole genome sequencing should be undertaken^[@CR22]^.

With this study, we extend the phenotypical and mutational spectrum of both *KMT2A*-associated WSS and *RNU4ATAC*-associated RS^[@CR7]--[@CR14]^. In family A, we identified a novel heterozygous splice site mutation in *KMT2A* causing in-frame deletion of exon 28. This deletion likely disrupts the stabilizing interaction site between the N- and C-terminal KMT2A fragments, resulting in loss of protein function^[@CR18]^. So far, we were unable to confirm this on a protein level because the KMT2A-N protein fragment was not reliably detectable by western blot. Further studies on protein level are planned in the future. Family A is the first published kindred to show autosomal dominant transmission of *KMT2A*-associated WSS in multiple generations, as previously reported cases were either sporadic or parents were unavailable^[@CR7]^. Remarkably, the characteristic hypertrichosis of elbows, back and/or lower limbs was absent in the here-reported WSS patients, confirming previous literature that this feature may not be as pathognomonic as initially believed^[@CR7],\ [@CR9],\ [@CR11],\ [@CR12]^. Interestingly, *KMT2A*-associated WSS shows phenotypical overlap with Kabuki syndrome type 1 caused by heterozygous mutations in the related gene *KMT2D* ^[@CR23]^. Over 80% of patients with *KMT2D*-associated Kabuki syndrome develop defects in terminal B cell differentiation resulting in antibody deficiency^[@CR23]^. Similarly, the here-described WSS patients demonstrated a block in terminal B cell differentiation evidenced by a relative increase in transitional and naive B cells and a relative decrease in switched memory B cells. Moreover, they had reduced levels of cTfh cells, which play a pivotal role in terminal B cell differentiation^[@CR20]^. Decreased cTfh cells have, to our knowledge, not been previously reported in WSS or Kabuki syndrome. It would be interesting to investigate cTfh cells in additional patients with *KMT2A*-associated WSS and *KMT2D*-associated Kabuki syndrome as this may help elucidate the underlying pathophysiology of the antibody deficiency. In summary, humoral immune deficiency in patients with WSS reported by us and by Stellacci *et al*.^[@CR7]^, and antibody deficiency in patients with heterozygous mutations in the related *KMT2D* gene^[@CR23]^, strongly suggest a previously unknown role for *KMT2A* in B cell biology that may be related with T helper cell function.

In family B, we identified rare compound heterozygous mutations in the noncoding *RNU4ATAC* gene, of which one mutation (c.116 A \> T) had not been associated with RS before^[@CR8]^. Although it was not initially apparent, with time the boy showed typical features of RS including spondyloepiphyseal dysplasia and retinal dystrophy^[@CR8]^. Curiously, he also demonstrated bilateral agenesis of the anterior cruciate ligaments and the 12^th^ ribs, which are not typically seen in RS^[@CR8]^. Spondyloepiphyseal or hip dysplasia have not yet been documented in the girl, currently 14 years old, although she displays mild growth retardation. Only recently, she was found to have mild fundus abnormalities suggestive of early stage retinal dystrophy. Note that retinal dystrophy was already evident in her brother at 7 years of age. It would be interesting to investigate why the girl has a milder phenotype than her brother. Since U4atac snRNA plays a role in minor intron splicing, it would be valuable to conduct RNA sequencing analysis in the two siblings and check for possible differences in intron retention^[@CR8]^. Detailed immunological workup in the RS patients revealed markedly decreased BAFF-R expression on B cells. To our knowledge, this finding has not been previously published. As BAFF-R signalling is important for survival of B cells in the peripheral blood, this may provide an important clue towards the B cell lymphopenia seen in RS patients^[@CR21]^. Moreover, analogous to the WSS patients, the RS siblings demonstrated decreased levels of cTfh cells, which may further compromise B cell differentiation and antibody production^[@CR20]^.

In conclusion, we here illustrate that a CVID phenotype can be the initial presentation of WSS and RS in early childhood while hallmark extra-immunological characteristics may be less prominent. With this, we highlight the importance of pursuing a genetic diagnosis in paediatric patients with an early-onset CVID phenotype, as this has important implications in terms of counselling, follow-up and screening for complications associated with the specific disorder.

Methods {#Sec10}
=======

Statement {#Sec11}
---------

All experiments and methods were carried out in accordance with relevant guidelines and regulations. The research protocol and all experimental protocols were approved by the ethical committee of Ghent University Hospital (2012/593). All reported subjects provided written informed consent for participation in the study, in accordance with the 1975 Helsinki Declaration.

Cytogenetic analyses {#Sec12}
--------------------

Microarray-based comparative genomic hybridization (array CGH) was performed on the affected sibling pairs of families A and B using the SurePrint G3 Human CGH Microarray Kit according to manufacturer's instructions (Agilent Technologies). Results were analyzed with arrayCGHbase^[@CR24]^. Karyotype analysis was performed on the family A twins using the conventional G-banding technique. To screen the family A twins for submicroscopic subtelomeric rearrangements, multiplex ligation-dependent probe amplification (MLPA) analysis was performed using SALSA P070 and SALSA P036C probe mixes according to manufacturer's instructions (MRC-Holland). To examine the family A twins for 22q11.2 deletion, fluorescence *in situ* hybridization (FISH) analysis was performed using the DiGeorge Region Probe Set -- LSI TUPLE 1 SpectrumOrange/LSI ARSA SpectrumGreen according to manufacturer's instructions (Vyvis).

WES {#Sec13}
---

Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation kit (Qiagen) according to manufacturer's instructions. Whole exome enrichment was performed with the SureSelectXT Human All Exon V5 + UTRs kit (Agilent Technologies). Paired-end massively parallel sequencing (100 cycles) was performed on a NextSeq 500 (Illumina). Read mapping against the human genome reference sequence (NCBI, GRCh37), and post-mapping duplicate read removal, quality-based variant calling and coverage analysis were performed with CLC Genomics Workbench v6.0.4 (CLC bio). Sequencing coverage is summarized in Supplementary Table [S1](#MOESM1){ref-type="media"}. Called variants with coverage ≥3 were annotated with Alamut Batch (Interactive Biosoftware). Only variants with population frequencies less than 10% were considered, according to public databases NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), NHLBI Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>), ExAC Browser (<http://exac.broadinstitute.org/>), and 1000 Genomes Project Browser (<http://browser.1000genomes.org/>). Variants were further prioritized based on allele frequency, functional prediction scores, nucleotide conservation scores and biological relevance^[@CR25]^. Both Mendelian and non-Mendelian inheritance patterns were taken into account. Afterwards, variants of interest were evaluated using Alamut Visual mutation interpretation software v2.7 rev. 1 (Interactive Biosoftware), Ingenuity Variant Analysis (QIAGEN, 2015 Release Spring), CADD scores v1.3 (<http://cadd.gs.washington.edu/home>), genome Aggregation Database (gnomAD) Browser (<http://gnomad.broadinstitute.org>), literature search, segregation analysis in available family members, and frequency in an in-house database containing variants of more than 1000 exomes at time of analysis.

Sanger sequencing of genomic DNA {#Sec14}
--------------------------------

DNA templates (GRCh37/hg19) of *KMT2A* (NM_001197104) and *RNU4ATAC* (NR_023343) were obtained from UCSC Genome Browser (<https://genome.ucsc.edu>). Primers for amplification and sequencing were designed with Primer3Plus^[@CR26]^. For *KMT2A* exon 28 and adjacent intron-exon borders (family A): forward primer 5′-CAACCCACAAGGGTGTCTTC-3′ and reverse primer 5′-GCCCGGCTAATTCTTTTTGT-3′. For the unique exon and intron-exon borders of *RNU4ATAC* (family B): forward primer 5′-TGGAGGCTGGAGGTAAGCTA-3′ and reverse primer 5′-TGAGGTGCAAAGACCTACTGAA-3′. Genomic DNA was amplified by PCR using the specific primers and KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically purified with Exonuclease I and Antartic phosphatase (both New England BioLabs Inc.). Purified PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqScape v2.5 (ThermoFisher Scientific).

RNA extraction, cDNA synthesis and confirmation of skipping of exon 28 in *KMT2A* {#Sec15}
---------------------------------------------------------------------------------

Total RNA was isolated from total PBMCs of all family A members and two control subjects by use of the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), according to manufacturer's instructions. The cDNA template (GRCh37/hg19) of *KMT2A* (NM_001197104) was obtained from UCSC Genome Browser (<https://genome.ucsc.edu>). Primers for amplification and sequencing of exon 28 and adjacent coding regions were designed with Primer3Plus^[@CR26]^: forward primer 5′-AACCCAAACCAAAAACCAAAC-3′ and reverse primer 5′-CATCAGTGGGGAGCTGAAAT-3′. *GAPDH* was used as a reference target: forward primer 5′-CAGCCTCAAGATCATCAGCA-3′ and reverse primer 5′-TGTGGTCATGAGTCCTTCCA-3′. PCR amplification was performed by use of GoTaq Hot Start Colorless Master Mix (Promega). PCR products were analyzed on a 2% agarose gel in 1x TBE buffer (Quality Biological Inc). SYBR Safe (Invitrogen) signals were captured with a Gel Doc EZ Imager system (Bio-Rad). In addition, purified PCR products were Sanger sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3130xL Genetic Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqMan (DNAStar).

Flow cytometric analysis of PBMCs {#Sec16}
---------------------------------

Immunophenotyping was performed on PBMCs of patients and age-matched healthy controls. PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient centrifugation and cryopreserved at −150 °C. Thawed PBMCs were stained with fixable viability dye 506 (eBioscience) and fluorescently labeled monoclonal antibodies under saturation conditions as previously described^[@CR19]^. Cells were acquired on an LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed with FlowJo version X (Tree Star Inc.).
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